{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:42:51Z","timestamp":1787071371451,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>The study aimed to report the outcomes of patients treated with cenegermin 0.002% for neurotrophic keratopathy (NK) following penetrating keratoplasty (PK).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This retrospective case series included patients evaluated at a tertiary care hospital who completed an 8-week course of cenegermin for NK within 12 months following PK. The primary outcome measure was NK stage, while secondary outcomes included complete epithelial healing, epithelial defect size, and best-corrected visual acuity (BCVA) at baseline and four time points during and following treatment. We also evaluated disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Fourteen eyes of 14 patients were included and demonstrated significant improvement in NK stage at 4 weeks (1.1 \u00b1 0.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006) and 8 weeks after treatment initiation (0.9 \u00b1 0.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) and 1 month (0.6 \u00b1 0.5;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and 6 months after treatment completion (0.8 \u00b1 0.9;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002) compared to baseline (1.6 \u00b1 0.5). Complete epithelial healing was noted 1 month (42.9%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016) and 6 months after treatment completion (38.5%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.016). Epithelial defect size improved to &lt;5 mm\n                      <jats:sup>2<\/jats:sup>\n                      at all points (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) during and after treatment compared to baseline (37.24 mm\n                      <jats:sup>2<\/jats:sup>\n                      ). Improvement in BCVA was not significant at any time point. Two (14.3%) patients experienced disease progression up to 6 months of follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Following an 8-week course of cenegermin, patients with a history of PK demonstrated improvement in NK stage, epithelial healing, and reduced epithelial defect size lasting 6 months after treatment completion. Patients with prior PK and NK may be considered candidates for cenegermin treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_311_24","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:00:18Z","timestamp":1750748418000},"page":"198-204","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Utility of cenegermin for the management of neurotrophic keratopathy after penetrating keratoplasty"],"prefix":"10.4103","volume":"18","author":[{"given":"Alexandra R.","family":"Zaloga","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Khalili","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon D.","family":"Ayres","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton D.","family":"Finklea","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beeran B.","family":"Meghpara","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Rapuano","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba A.","family":"Syed","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA"},{"name":"Cornea Service, Wills Eye Hospital, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"R1-20250628","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.survophthal.2013.09.002","article-title":"Corneal nerves in health and disease","volume":"59","author":"Shaheen","year":"2014","journal-title":"Surv Ophthalmol"},{"key":"R2-20250628","first-page":"571","article-title":"Diagnosis and management of neurotrophic keratitis","volume":"8","author":"Sacchetti","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R3-20250628","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye (Lond)"},{"key":"R4-20250628","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08820538.2021.1900282","article-title":"Advances in the medical management of neurotrophic keratitis","volume":"36","author":"Dohlman","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"R5-20250628","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0039-6257(87)90102-0","article-title":"Management of noninfectious corneal ulcers","volume":"32","author":"Donzis","year":"1987","journal-title":"Surv Ophthalmol"},{"key":"R6-20250628","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.survophthal.2011.06.003","article-title":"Management of corneal perforation","volume":"56","author":"Jhanji","year":"2011","journal-title":"Surv Ophthalmol"},{"key":"R7-20250628","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","article-title":"Cenegermin: A review in neurotrophic keratitis","volume":"80","author":"Deeks","year":"2020","journal-title":"Drugs"},{"key":"R8-20250628","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/OPTH.S185184","article-title":"Update on cenegermin eye drops in the treatment of neurotrophic keratitis","volume":"13","author":"Sheha","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"R9-20250628","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"R10-20250628","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13023-022-02237-5","article-title":"Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy","volume":"17","author":"Pedrotti","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R11-20250628","first-page":"617","article-title":"Role of topical cenegermin in management of a cornea transplant in a functionally monocular patient with neurotrophic keratitis and facial nerve palsy: A case report","volume":"13","author":"Pocobelli","year":"2020","journal-title":"Int Med Case Rep J"},{"key":"R13-20250628","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"R16-20250628","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/cc1820","article-title":"Statistics review 6: Nonparametric methods","volume":"6","author":"Whitley","year":"2002","journal-title":"Crit Care"},{"key":"R17-20250628","doi-asserted-by":"crossref","first-page":"101649","DOI":"10.1016\/j.ajoc.2022.101649","article-title":"Topical human recombinant nerve growth factor for stage 1 neurotrophic keratitis: Retrospective case series of cenegermin treatment","volume":"27","author":"Epitropoulos","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R18-20250628","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ophtha.2022.08.014","article-title":"Efficacy of recombinant human nerve growth factor in stage 1 neurotrophic keratopathy","volume":"129","author":"Yavuz Saricay","year":"2022","journal-title":"Ophthalmology"},{"key":"R19-20250628","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13023-022-02236-6","article-title":"Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: A novel cure for a rare degenerative corneal disease?","volume":"17","author":"Bruscolini","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"R20-20250628","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1007\/s10792-021-01982-z","article-title":"An attempt to optimize the outcome of penetrating keratoplasty in congenital aniridia-associated keratopathy (AAK)","volume":"41","author":"Farah","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R21-20250628","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.15537\/smj.2016.9.14075","article-title":"Outcome of repeat penetrating keratoplasty in eyes with failed penetrating keratoplasty","volume":"37","author":"Khairallah","year":"2016","journal-title":"Saudi Med J"},{"key":"R22-20250628","doi-asserted-by":"crossref","first-page":"707242","DOI":"10.3389\/fmed.2021.707242","article-title":"Post-keratoplasty infectious keratitis: Epidemiology, risk factors, management, and outcomes","volume":"8","author":"Song","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R23-20250628","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00417-021-05431-6","article-title":"Long-term clinical outcome and satisfaction survey in patients with neurotrophic keratopathy after treatment with cenegermin eye drops or amniotic membrane transplantation","volume":"260","author":"Sacchetti","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_311_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:45:05Z","timestamp":1787067905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_311_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_311_24","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-09-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}